Compare Lucid Group Inc (LCID) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs TransMedics Group Inc — how do they compare? Lucid Group Inc trades at $6.45 (market cap $2.64B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| LCID | TMDX | |
|---|---|---|
Market Cap | $2.64B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.77 | $150.42 |
52-Week Low | $4.62 | $61.99 |
Enterprise Value | $5.54B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.47, down 2.12% on the day, reflecting ongoing investor concerns over persistent losses and cash burn. The stock exhibits a bearish technical trend with key support at $6, while fundamentally, the company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by a -249.21% net income margin. Recent news highlights an operational reset aiming for $1.4 billion in cash savings and a delayed midsize EV launch to 2027.
The outlook remains challenging with significant execution risks, though a $10.50 analyst price target suggests potential upside if cost-cutting and new initiatives like robotaxi partnerships succeed. High cash burn and competitive pressures pose substantial risks to near-term stability.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
